Rituximab Hypersensitivity: From Clinical Presentation to Management
Rituximab is a chimeric monoclonal antibody (mAb) against CD20 molecule which is expressed on human B cells. It has been used for the treatment of various lymphoid malignancies, lymphoproliferative diseases, and rheumatologic disorders. Rituximab is generally well tolerated. However, increased use o...
Saved in:
Main Authors: | Ghada E. Fouda (Author), Sevim Bavbek (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Severe Pemphigus Vulgaris Resistant to Conventional Therapies and with Hypersensitivity to Rituximab in a 12-Year-Old Child
by: Maria Beatrice De Felici Del Giudice, et al.
Published: (2023) -
Rituximab Use in the Management of Childhood Nephrotic Syndrome
by: Mahmoud Kallash, et al.
Published: (2019) -
ISP good clinical practice recommendations for the management of dentin hypersensitivity
by: Vishakha Grover, et al.
Published: (2022) -
The etiology and management of dentinal hypersensitivity
by: Samuel O. Arua, et al.
Published: (2021) -
Clinical efficacy and safety of rituximab in lupus nephritis
by: Zhong Z, et al.
Published: (2019)